Skip to main
ARDX
ARDX logo

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc demonstrated significant financial performance with total revenue surpassing consensus expectations by approximately $16 million, attributed in part to an $8 million beat from its IBSRELA product. The company reported a robust 27% quarter-over-quarter growth, excluding one-time benefits, and reiterated its peak U.S. revenue guidance of $750 million before patent expiration. Furthermore, XPHOZAH's U.S. net sales exceeded consensus by around $3 million, indicating early success in the company's strategy to adapt to the changing Medicare Part D coverage landscape.

Bears say

Ardelyx Inc. faces a challenging financial outlook due to the recent loss of Medicare Part D coverage for its product Xphozah, which could significantly impact revenues. Despite efforts to target the non-Medicare patient population, making up approximately 40% of the market, the absence of financial guidance for fiscal year 2025 introduces heightened uncertainty regarding future performance. This combination of coverage challenges and lack of forward guidance creates a precarious situation that may hinder investor confidence in the company's stock.

Ardelyx (ARDX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Buy based on their latest research and market trends.

According to 9 analysts, Ardelyx (ARDX) has a Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.